Drugs that contain Lanthanum Carbonate

1. List of Fosrenol drug patents

FOSRENOL's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7465465 TAKEDA PHARMS USA Pharmaceutical formulation comprising lanthanum compounds
Aug, 2024

(1 year, 2 months from now)

US7381428 TAKEDA PHARMS USA Stabilized lanthanum carbonate compositions
Aug, 2024

(1 year, 2 months from now)

US9023397 TAKEDA PHARMS USA Capsule and powder formulations containing lanthanum compounds
Dec, 2030

(7 years from now)

US8980327 TAKEDA PHARMS USA Capsule and powder formulations containing lanthanum compounds
Dec, 2030

(7 years from now)

Do you want to check out FOSRENOL patents from before 2022?

Market Authorisation Date: 24 September, 2014

Treatment: Reduction of serum phosphate in patients with end stage renal disease

Dosage: POWDER;ORAL

How can I launch a generic of FOSRENOL before it's patent expiration?
More Information on Dosage

FOSRENOL family patents

14

United States

7

Japan

6

European Union

5

Denmark

4

Spain

4

Poland

4

China

4

Canada

4

Cyprus

4

Portugal

4

Australia

4

Slovenia

3

Brazil

EA

3

EA

3

Korea, Republic of

2

Austria

2

Germany

2

Norway

2

South Africa

2

Hungary

IB

1

IB

1

Hong Kong

1

Iceland

1

Czech Republic

1

Singapore

1

Argentina

1

New Zealand

1

Peru

1

Israel

1

Taiwan

1

Mexico

1

Finland

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic